Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Policy / Regulatory

China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP

Fineline Cube Dec 27, 2023

The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...

Company Medical Device

Fresenius Medical Care Expands Dialysis Solutions in China with 6008 CARESystem Launch

Fineline Cube Dec 27, 2023

Fresenius Medical Care AG has announced the official launch of its 6008 CARESystem hemodialysis filtration...

Policy / Regulatory

China Charts Course for Advanced Disease Prevention and Control System by 2030

Fineline Cube Dec 27, 2023

China’s State Council has issued the “Guiding Opinions on Promoting the High Quality Development of...

Company Deals

Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug

Fineline Cube Dec 27, 2023

China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....

Company Drug

Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA

Fineline Cube Dec 27, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...

Company Drug

Konruns Pharmaceutical Receives NMPA Go-Ahead for KC1036 Esophageal Cancer Study

Fineline Cube Dec 27, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...

Company Deals

Jianzhijia Health-Chain to Purchase Local Drug Retailer for $23.5 Million

Fineline Cube Dec 27, 2023

Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266), a Chinese healthcare company, has announced plans to...

Company Drug

Simcere Affiliate Shanghai Simnova Biotech Gets China Nod for CAR-T Therapy SNC109

Fineline Cube Dec 27, 2023

Shanghai Simnova Biotech Co., Ltd, known as Simnova outside of China and an affiliate of...

Company Deals

Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment

Fineline Cube Dec 27, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have...

Company Deals

Aidea Pharmaceutical Co. Terminates ACC006 Technology Transfer Deal with Lixin Bio

Fineline Cube Dec 27, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement...

Company Deals

AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal

Fineline Cube Dec 26, 2023

Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies...

Policy / Regulatory

China’s NHC Releases Third List of Recommended Generic Drugs for Development

Fineline Cube Dec 26, 2023

The National Health Commission (NHC) of China has released its third list of drugs recommended...

Company Drug

FDA Grants Priority Review to MSD and Daiichi Sankyo’s ADC for Lung Cancer

Fineline Cube Dec 26, 2023

The US Food and Drug Administration (FDA) has accepted under priority review a filing from...

Company Deals Drug

AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial

Fineline Cube Dec 26, 2023

AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...

Policy / Regulatory

Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List

Fineline Cube Dec 26, 2023

Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel...

Company Drug

J&J’s Rybrevant-Lazertinib Combo Accepted for FDA Review in NSCLC

Fineline Cube Dec 26, 2023

The US Food and Drug Administration (FDA) has accepted for review Johnson & Johnson’s (J&J;...

Policy / Regulatory

Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products

Fineline Cube Dec 26, 2023

The Hunan Healthcare Security Administration has published a list of 226 drugs to be included...

Company Drug

Shanghai Fosun to Exclusively Commercialize Generic Entresto in China

Fineline Cube Dec 26, 2023

Nanjing F&S Pharmatech Co., Ltd has officially launched its generic version of Novartis’s heart failure...

Company Drug

Shouyao Holdings Receives Ethical Approval for Phase III Study of ALK Inhibitor SY-3505

Fineline Cube Dec 26, 2023

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received ethical...

Hospital

Hengrui Pharmaceuticals-Backed Nanjing Tianyinshan Hospital Opens as Class 3A Oncology Specialist Center

Fineline Cube Dec 26, 2023

Nanjing Tianyinshan Hospital, a private Class 3A oncology specialist hospital invested in by Hengrui Pharmaceuticals...

Posts pagination

1 … 463 464 465 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.